PAREXEL International Corporation (PRXL) is a global biopharmaceutical services company that offers a range of clinical research, consulting, medical communications, and technology solutions to the life sciences industry. The company's services include clinical research, regulatory consulting, market access consulting, medical communications, and technology solutions such as its Perceptive MyTrials clinical trial management platform.
PAREXEL was founded in 1982 and is headquartered in Waltham, Massachusetts. The company has operations in more than 100 countries and employs more than 18,000 people worldwide.
As of February 25, 2023, the market capitalization of PAREXEL International Corporation was approximately $8.6 billion. The company's stock is traded on the NASDAQ stock exchange under the ticker symbol PRXL.
PAREXEL International Corporation (PRXL) is a global biopharmaceutical services company that offers a range of clinical research, consulting, medical communications, and technology solutions to the life sciences industry. The company's services include clinical research, regulatory consulting, market access consulting, medical communications, and technology solutions such as its Perceptive MyTrials clinical trial management platform.